Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5171-5177

  Thomas Schoemann, Audrey ^a,b   Batteux, Frédéric ^a   Mongaret, Céline ^a   Nicco, Carole ^a   Chéreau, Christiane ^a   Annereau, Maxime ^a   Dauphin, Alain ^b   Goldwasser, François ^b   Weill, Bernard ^a   Lemare, François ^a,c   Alexandre, Jérôme ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2'7' DICHLORODIHYDROFLUORESCEIN DIACETATE; 4,5 DIAMINOFLUORESCEIN DIACETATE; ARSENIC TRIOXIDE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; FLUORESCEIN DERIVATIVE; MANGANESE TETRAKIS (5,10,15,20)BENZOIC ACID PORPHYRIN; N(G) NITROARGININE METHYL ESTER; PORPHYRIN DERIVATIVE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER MODEL; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MOUSE; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T CELL DEPLETION;

ANIMALS; ARSENICALS; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLUORESCEIN; FLUORESCEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METALLOPORPHYRINS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; OXIDES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; T-LYMPHOCYTES, REGULATORY;

EID: 84869793887     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103094     Document Type: Article

References (31)

1. Lizée, G., M. A. Cantu, and P. Hwu. 2007. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin. Cancer Res. 13: 5250-5255. (Pubitemid 47510347)
2. Moschella, F., E. Proietti, I. Capone, and F. Belardelli. 2010. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. N. Y. Acad. Sci. 1194: 169-178.
3. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321. (Pubitemid 16002234)
4. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101: 429-441. (Pubitemid 28067341)
5. Medina-Echeverz, J., J. Fioravanti, M. Zabala, N. Ardaiz, J. Prieto, and P. Berraondo. 2011. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186: 807-815.
6. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
7. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. (Pubitemid 39255944)
8. Lutsiak, M. E., R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, and H. Sabzevari. 2005. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868. (Pubitemid 40446280)
9. Ghiringhelli, F., C. Menard, P. E. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Le Cesne, L. Zitvogel, and B. Chauffert. 2007. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56: 641-648. (Pubitemid 46348738)
10. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949. (Pubitemid 39273735)
11. Alvaro, T., M. Lejeune, M. T. Salvadó, R. Bosch, J. F. García, J. Jaén, A. H. Banham, G. Roncador, C. Montalbán, and M. A. Piris. 2005. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11: 1467-1473. (Pubitemid 40315228)
12. Mougiakakos, D., A. Choudhury, A. Lladser, R. Kiessling, and C. C. Johansson. 2010. Regulatory T cells in cancer. Adv. Cancer Res. 107: 57-117.
13. Zhang, T. D., G. Q. Chen, Z. G. Wang, Z. Y. Wang, S. J. Chen, and Z. Chen. 2001. Arsenic trioxide, a therapeutic agent for APL. Oncogene 20: 7146-7153. (Pubitemid 33105004)
14. Trachootham, D., J. Alexandre, and P. Huang. 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8: 579-591.
15. Miller, W. H., Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman. 2002. Mechanisms of action of arsenic trioxide. Cancer Res. 62: 3893-3903. (Pubitemid 34792653)
16. Bobé, P., D. Bonardelle, K. Benihoud, P. Opolon, and M. K. Chelbi-Alix. 2006. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108: 3967-3975. (Pubitemid 44913262)
17. Deaglio, S., D. Canella, G. Baj, A. Arnulfo, S. Waxman, and F. Malavasi. 2001. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk. Res. 25: 227-235. (Pubitemid 32157020)
18. Baj, G., A. Arnulfo, S. Deaglio, R. Mallone, A. Vigone, M. G. De Cesaris, N. Surico, F. Malavasi, and E. Ferrero. 2002. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res. Treat. 73: 61-73. (Pubitemid 34548166)
19. Awwad, M., and R. J. North. 1989. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49: 1649-1654. (Pubitemid 19108381)
20. Gupta, S., L. Yel, D. Kim, C. Kim, S. Chiplunkar, and S. Gollapudi. 2003. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol. Cancer Ther. 2: 711-719.
21. Malvicini, M., M. Rizzo, L. Alaniz, F. Piñero, M. García, C. Atorrasagasti, J. B. Aquino, V. Rozados, O. G. Scharovsky, P. Matar, and G. Mazzolini. 2009. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res. 15: 7256-7265.
22. Curiel, T. J. 2008. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 20: 241-246.
23. Bracci, L., F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, and E. Proietti. 2007. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13: 644-653. (Pubitemid 46225372)
24. Disis, M. L. 2010. Immune regulation of cancer. J. Clin. Oncol. 28: 4531-4538.
25. Uslu, R., U. A. Sanli, C. Sezgin, B. Karabulut, E. Terzioglu, S. B. Omay, and E. Goker. 2000. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 6: 4957-4964. (Pubitemid 32110442)
26. Liu, B., S. Pan, X. Dong, H. Qiao, H. Jiang, G. W. Krissansen, and X. Sun. 2006. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 97: 675-681. (Pubitemid 44056616)
27. Pelicano, H., L. Feng, Y. Zhou, J. S. Carew, E. O. Hileman, W. Plunkett, M. J. Keating, and P. Huang. 2003. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278: 37832-37839. (Pubitemid 37175311)
28. Chou, W. C., C. Jie, A. A. Kenedy, R. J. Jones, M. A. Trush, and C. V. Dang. 2004. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc. Natl. Acad. Sci. USA 101: 4578-4583. (Pubitemid 38437453)
29. Lemarie, A., E. Bourdonnay, C. Morzadec, O. Fardel, and L. Vernhet. 2008. Inorganic arsenic activates reduced NADPH oxidase in human primary macrophages through a Rho kinase/p38 kinase pathway. J. Immunol. 180: 6010-6017.
30. Lynn, S., J. N. Shiung, J. R. Gurr, and K. Y. Jan. 1998. Arsenite stimulates poly (ADP-ribosylation) by generation of nitric oxide. Free Radic. Biol. Med. 24: 442-449. (Pubitemid 28008789)
31. Wang, J., L. Li, H. Cang, G. Shi, and J. Yi. 2008. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk. Res. 32: 429-436. (Pubitemid 351295909)